Supplemental Figure 2:
In vivo treatment with plerixafor sensitizes leukemic blasts to AraC Leukemic mice were treated according to the treatment schema outlined in Figure 3C . Leukemic burden was quantified as the absolute blast count in each individual primary sample: (A) MLL1, (B) MLL2, (C) MLL3, and (D) MLL4. (E) Pathologic specimens from MLL1-transplanted mice. BM, bone marrow. *p<0.05, **p<0.01, ***p<0.001 vs. control. †p<0.05, ‡p<0.01 vs AraC. 
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Supplemental Figure 5:
The effects of extended treatment with plerixafor on surface CXCR4 expression persist over time Cell lines were treated with plerixafor or vehicle control for 72 hours. Cells were then washed and resuspended in fresh medium. Following withdrawal of plerixafor, cells were harvested for flow cytometry at various time points for an additional 72 hours. Surface expression of CXCR4 was measured using 12G5, 1D9, and 2B11 antibodies. Results for (A) Nalm-6 10 nM, (B) Nalm-6 100 nM, (C) HB-1119 10 nM, and (D) HB-1119 100 nM.
